Glycyrrhetinic acid inhibits non-small cell lung cancer via promotion of Prdx6- and caspase-3-mediated mitochondrial apoptosis

Biomed Pharmacother. 2024 Apr:173:116304. doi: 10.1016/j.biopha.2024.116304. Epub 2024 Feb 23.

Abstract

Glycyrrhetinic acid (GA) shows great efficiency against non-small cell lung cancer (NSCLC), but the detailed mechanism is unclear, which has limited its clinical application. Herein, we investigated the potential targets of GA against NSCLC by activity-based protein profiling (ABPP) technology and the combination of histopathology and proteomics validation. In vitro and in vivo results indicated GA significantly inhibited NSCLC via promotion of peroxiredoxin-6 (Prdx6) and caspase-3 (Casp3)-mediated mitochondrial apoptosis. This original finding will provide theoretical and data support to improve the treatment of NSCLC with the application of GA.

Keywords: Activity-based protein profiling; Glycyrrhetinic acid; NSCLC.

MeSH terms

  • Apoptosis
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Caspase 3
  • Cell Line, Tumor
  • Glycyrrhetinic Acid* / pharmacology
  • Humans
  • Lung Neoplasms* / pathology
  • Peroxiredoxin VI / therapeutic use

Substances

  • Glycyrrhetinic Acid
  • Caspase 3
  • Peroxiredoxin VI